Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01259297 · ClinicalTrials.gov registry record · Phase 3
A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,336
- Enrollment target
NCT01259297 is a Phase 3 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 2,336 participants.
The verdict
NCT01259297, a Phase 3 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,336 participants
- Enrollment target
Study Summary
This study was planned to provide new information regarding the role of aliskiren (with or without additional therapy with a diuretic or a Calcium channel blockers (CCB)) in elderly individuals (≥ 65 years) with systolic blood pressure (SBP) 130 to 159 mmHg, in preventing major cardiovascular (CV) events and on global measures of physical, executive and cognitive function.
Interventions
- DRUG Amlodipine
- DRUG Aliskiren
- DRUG Placebo for Aliskiren
- DRUG Hydrochlorothiazide (HCTZ)
- DRUG Placebo for Amlodipine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,336 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01259297
The ClinicalTrials.gov registry entry for NCT01259297 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2,336 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Amlodipine is the first listed.
NCT01259297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01259297 about?
NCT01259297 is a clinical study titled "A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People". This study was planned to provide new information regarding the role of aliskiren (with or without additional therapy with a diuretic or a Calcium channel blockers (CCB)) in elderly individuals (≥ 65 years) with systolic blood pressure (SBP) 130 to 159 mmHg, in preventing major cardiovascular (CV) e...
What is the current status of trial NCT01259297?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,336 participants. The study started on 2011-01. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01259297?
The interventions under investigation include: Amlodipine (DRUG), Aliskiren (DRUG), Placebo for Aliskiren (DRUG), Hydrochlorothiazide (HCTZ) (DRUG), Placebo for Amlodipine (DRUG).
Who is sponsoring clinical trial NCT01259297?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.